Title: Clinical observation of Captopril Tablet combined with Zhenju Hypotensive Tablet in treatment of primary hypertension in gerontal patients
Abstract: Objective To observe the efficacy of Captopril Tablets combined with Zhenju Hypotensive Tablets(CT-ZHT) in the treatment of primary hypertension in gerontal patients of Jiangwan Community Health Center of Hongkou District of Shanghai. Methods The elderly patients(68 cases) with primary hypertension were randomly divided into the treatment(34 cases) and control(34 cases) groups. The patients in the control group were given CT 12.5 mg for three times every day during four weeks and the patients in the treatment group were given CT 12.5 mg and ZHT 0.48 g for three times every day for four weeks. Blood pressure was measured before and after treatment.. All the participants were closely observed and recored of any adverse reactions. Results After treatment, the blood pressure was significantly lower than before treatment with significant difference(P 0.05). At the end of week 4,The systolic blood pressure of treatment and control groups decreased by 14.3% and 8.4% respectively, with statistically significant difference(P 0.05); Diastolic blood pressure decreased by 22.7% and 19.3% respectively, with statistically significant difference(P 0.05). The antihypertensive effective rates in the treatment and control groups were 97.1% and 85.3%, respectively. There were obvious differences in the effects of both hypotensive drugs(P0.05). Blood routine examination, routine urine test, blood lipids, blood glucose, liver and kidney function showed no abnormality. Few adverse reactions were observed in both groups and the difference was no remarkable statistically. Conclusion CT-ZHT in the treatment of primary hypertension has good antihypertensive effect in elderly patients with primary hypertension, producing few side effects and well patient compliance.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot